Study explorer (study characteristics and results) method abbreviations

display ongoing studies
Study studied treatmentcontrol treatmentpatientsrisk of biassample sizes Results

COVID 19 all comers meta-analysis

ChiCTR2000030054-HCQ (Chen), 2020
 
ChiCTR2000030054
RCThydroxychloroquinestandard of careCOVID 19 all comershigh
18/12 inconclusive
    no demonstrated benefit a
Gautret et al., 2020NRahydroxychloroquinecontrolCOVID 19 all comersserious
20/16 suggested
  • suggested 15.3-fold increase in PCR-negative conversion (PE) but with a low degree of certainty due to high risk of bias
a viral load reduction/disappearance is claimed but the numerous methological limits preclude any strong conclusion

COVID 19 hospitalized meta-analysis

Abd-Elsalam, 2020
 
NCT04353336
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
97/97 inconclusive
    no demonstrated benefit a
ARCHAIC -hydroxychloroquine, 2020
 
NL8490
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
9/6 inconclusive
    no demonstrated benefit a
CCAP-1, 2020
 
NCT04345289
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
-/- inconclusive
    no demonstrated benefit a
Chen, 2020
 
NCT04384380
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
21/12 inconclusive
    no demonstrated benefit a
Duke university HCQ, 2020
 
NCT04335552
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
4/2 no results
    discontinued, found in Axfors et al. meta-analysis
    HAHPS, 2020
     
    NCT04329832
    RCThydroxychloroquineazithromycinCOVID 19 hospitalizedsome concern
    42/43 inconclusive
      no demonstrated benefit a
    • inconclusive 7 % increase in clinical worsening (PE) with a moderate degree of certainty due to some concern in risk of bias
    Huang, 2020
     
    ChiCTR2000029542
    RCTchloroquinelopinavir/ritonavirCOVID 19 hospitalizedsome concern
    10/12 inconclusive
      no demonstrated benefit a
    HYCOVID, 2020
     
    NCT04325893
    RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
    124/123 inconclusive
      no demonstrated benefit a
    • inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
    NO COVID-19 (Lyngbakken), 2020
     
    NCT04316377
    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
    27/26 inconclusive
      no demonstrated benefit a
    OAHU-COVID19, 2020
     
    NCT04345692
    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
    10/6 inconclusive
      no demonstrated benefit a
    ORCHID, 2020
     
    NCT04332991
    RCThydroxychloroquineplaceboCOVID 19 hospitalizedlow
    242/237 inconclusive
      no demonstrated benefit a
    • inconclusive 2 % increase in clinical improvement (PE) with a high degree of certainty due to low risk of bias
    PROTECT B, 2020
     
    NCT04338698
    RCThydroxychloroquineoseltamivirCOVID 19 hospitalizedNA
    -/- inconclusive
      no demonstrated benefit a
    RECOVERY, 2020
     
    NCT04381936
    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
    1561/3155 safety concern
    • inconclusive 9 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 14 % increase in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
    SOLIDARITY (WHO study) HCQ, 2020
     
    NCT04315948
    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
    947/906 inconclusive
    • inconclusive 19 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    Tang, 2020
     
    ChiCTR2000029868
    RCTchloroquine and derivativesstandard of careCOVID 19 hospitalizedhigh
    75/75 inconclusive
      no demonstrated benefit a
    Tang, 2020
     
    ChiCTR2000029868
    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedhigh
    75/75 safety concern
      no demonstrated benefit a
    • statistically significant 3.5-fold increase in adverse events but with a low degree of certainty due to high risk of bias
    TEACH, 2020
     
    NCT04369742
    RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
    67/61 inconclusive
      no demonstrated benefit a
    • inconclusive 80 % increase in clinical worsening (PE) with a moderate degree of certainty due to some concern in risk of bias
    • inconclusive 16 % increase in adverse events (PE) with a moderate degree of certainty due to some concern in risk of bias
    Arshad (HCQ), 2020OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
    1202/409 suggested
    • suggested 66 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
    Belgian Collaborative Group on COVID-19, 2020OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
    4542/3533 suggested
    • suggested 32 % decrease in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
    Chen, 2020OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
    163/121 safety concern
    • statistically significant 51 % decrease in clinical improvement,clinical improvement (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
    Chen, 2020OBSchloroquinecontrolCOVID 19 hospitalizedcritical
    163/121 inconclusive
      no demonstrated benefit a
    Geleris, 2020OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
    811/565 inconclusive
      no demonstrated benefit a
    Huang, 2020OBSchloroquinecontrolCOVID 19 hospitalizedcritical
    197/176 suggested
    • suggested 5.1-fold increase in PCR-negative conversion (14-day) but with a very low degree of certainty due to critical risk of bias
    Magagnoli (HC), 2020OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
    97/158 safety concern
    • safety concern with statistically significant 1.6-fold increase in deaths,deaths (time to event analysis only)
    Novales, 2020OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
    123/43 suggested
    • suggested 93 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
    Paccoud, 2020OBShydroxychloroquinestandard of careCOVID 19 hospitalizedserious
    38/46 inconclusive
      no demonstrated benefit a
    Rosenberg, 2020OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
    -/- safety concern
      no demonstrated benefit a
    • safety concern with 91 % increase in cardiac arrest (not statistically significant)
    Sbidian (HCQ alone), 2020OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
    623/3792 safety concern
    • statistically significant 25 % increase in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
    Singh, 2020OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
    -/- inconclusive
      no demonstrated benefit a

    COVID-19 mild to moderate meta-analysis

    Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020
     
    NCT04322123
    RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
    221/227 safety concern
      no demonstrated benefit a
    • statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
    HC-nCoV (Shanghai), 2020
     
    NCT04261517
    RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
    15/15 inconclusive
      no demonstrated benefit a
    NCT04333654, 2020
     
    NCT04333654
    RCThydroxychloroquinestandard of careCOVID-19 mild to moderateNA
    -/- inconclusive
      no demonstrated benefit a
    NCT04342650, 2020
     
    NCT04342650
    RCTchloroquineplaceboCOVID-19 mild to moderateNA
    -/- inconclusive
      no demonstrated benefit a
    Zhaowei Chen, 2020
     
    ChiCTR2000029559
    RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
    31/31 suggested
    • suggested 2.4-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias
    • suggested 2.4-fold increase in radiologic improvement (7-day) but with a low degree of certainty due to high risk of bias
    Zhaowei Chen, 2020
     
    ChiCTR2000029559
    RCThydroxychloroquinecontrolCOVID-19 mild to moderatehigh
    31/31 inconclusive
      no demonstrated benefit a
    Min, 2020OBShydroxychloroquinecontrolCOVID-19 mild to moderateNA
    20/20 inconclusive
      no demonstrated benefit a

    COVID-19 severe or critically meta-analysis

    HYDRA, 2020
     
    NCT04315896
    RCThydroxychloroquineplaceboCOVID-19 severe or criticallyNA
    75/77 inconclusive
    • inconclusive 1 % decrease in deaths (PE)
    REMAP-CAP-HCQ, 2020
     
    NCT02735707
    RCThydroxychloroquinestandard of careCOVID-19 severe or criticallyNA
    61/81 inconclusive
    • inconclusive 4 % increase in deaths (PE)
    REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.multi-arm study
    Mahevas, 2020OBShydroxychloroquinestandard of careCOVID-19 severe or criticallyserious
    84/97 inconclusive
      no demonstrated benefit a
    Yu, 2020OBShydroxychloroquinecontrolCOVID-19 severe or criticallycritical
    48/520 suggested
    • suggested 68 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);